BCL2 and hepatocellular carcinoma: DHM can downregulate Notch1 expression and decrease the Bcl-2/Bax ratio in hepatoma cell lines QGY7701 and HepG2 in a time- and dose-dependent manner, inhibiting the proliferation of hepatoma cells [67].